Transcranial Magnetic Stimulation for Chronic Neuropathic Pain

StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Sep 20, 2026 → Dec 30, 2026
See other at-risk trials from University of California, San Francisco

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Primary completion pushed from Sep 20, 2026 to Dec 30, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 7 of 9 entries
    • Study description revised
    • Publications: details revised at 10 of 10 entries
  2. Notable Primary completion date: Dec 30, 2025 to Sep 20, 2026v8 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jan 30, 2026 to Dec 30, 2026
    • Site details revised
    • Collaborators expanded, about 4 words
  3. Notable Enrollment target: 20 to 32
    • Primary completion date: Dec 30, 2024 to Dec 30, 2025
    • Study completion date: Jan 30, 2025 to Jan 30, 2026
    v7
  4. Minor 4 versions Re-verified since May 24, 2023, no change to tracked fieldsv3-v6
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 1, 2022 to Apr 25, 2022
    • Site details revised
    v2
  6. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Chronic neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous system. It is highly prevalent, debilitating, and challenging to treat. Current available treatments have low efficacy, high side effect burden, and are prone to misuse and dependence. Emerging evidence suggests that the transition from acute to chronic neuropathic pain is associated with reorganization of central brain circuits involved in pain processing. Repetitive transcranial magnetic stimulation (rTMS) is a promising alternative treatment that uses focused magnetic pulses to non-invasively modulate brain activity, a strategy that can potentially circumvent the adverse effects of available treatments for pain. RTMS is FDA-approved for the treatment of major depressive disorder, obsessive-compulsive disorder, and migraine, and has been shown to reduce pain scores when applied to the contralateral motor cortex (M1). However, available studies of rTMS for chronic neuropathic pain typically show variable and often short-lived benefits, and many aspects of optimal treatment remain unknown, including ideal rTMS stimulation parameters, duration of treatment, and relationship to the underlying pain etiology. Here the investigators propose to evaluate the efficacy of high frequency rTMS to M1, the region with most evidence of benefit in chronic neuropathic pain, and to use functional magnetic resonance imaging (fMRI) to identify alternative rTMS targets for participants that do not respond to stimulation at M1. The central aim is to evaluate the pain relieving efficacy of multi-session high-frequency M1 TMS for pain. In secondary exploratory analyses, the investigator propose to investigate patient characteristic that are predictive of responsive to M1 rTMS and identify viable alternative stimulation targets in non-responders to M1 rTMS.
Trial Details
NCT Number NCT05593237
Lead Sponsor University of California, San Francisco
Collaborators: Facial Pain Research Foundation
Conditions
(from sponsor)
Chronic Neuropathic Pain, Post-Stroke Pain, Trigeminal Neuralgia, Nerve Injury, Spinal Cord Injuries, Pain, Postoperative, Complex Regional Pain Syndromes, Post-herpetic Neuralgia +1 more
Related terms Complex Regional Pain Syndromes, Neuralgia, Neuralgia, Postherpetic, Pain, Postoperative Pain, Radiculopathy, Spinal Cord Injuries, Trigeminal Neuralgia
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov